Sfrowasa
Proctitis, Proctocolitis, Colitis, Ulcerative + 2 more
Treatment
1 FDA approval
0 Active Studies for Sfrowasa
Treatment for
Proctitis
What is Sfrowasa
Mesalazine
The Generic name of this drug
Treatment Summary
Mesalazine is a medication used to reduce inflammation and treat inflammatory bowel diseases like ulcerative colitis. It is related to aspirin and other anti-inflammatory drugs. Mesalazine has been in use since the 1970s, but has historically had issues with stability. In recent decades, researchers have developed stable formulations of mesalazine, making it easier to take and more effective. Current research into mesalazine suggests it may reduce the risk of colorectal cancer in some cases.
Rowasa
is the brand name
Sfrowasa Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Rowasa
Mesalazine
1988
107
Approved as Treatment by the FDA
Mesalazine, otherwise called Rowasa, is approved by the FDA for 1 uses which include Crohn Disease .
Crohn Disease
Effectiveness
How Sfrowasa Affects Patients
Mesalazine is one of the two main ingredients in sulphasalazine, with the other being sulphapyridine. It is thought to reduce inflammation by blocking the production of certain substances that cause swelling and by preventing white blood cells from moving to the site of inflammation. It is believed to work better when applied directly to the skin rather than taken orally. In some medical studies, mesalazine was found to be just as effective as prednisolone or sulphasalazine in reducing inflammation in mice and guinea pigs with colitis.
How Sfrowasa works in the body
The exact way mesalazine works is not completely known. It likely reduces inflammation in the colon by blocking the production of certain molecules, like prostaglandins and leukotrienes. It may also activate certain receptors in the colonic/rectal epithelium and inhibit an enzyme called iNOS. Additionally, it might stop the movement of white blood cells to the inflamed area, decrease cytokine production, and neutralize free radicals.
When to interrupt dosage
The measure of Sfrowasa is contingent upon the established condition. The amount likewise fluctuates as per the technique of delivery laid out in the table beneath.
Condition
Dosage
Administration
Proctitis
400.0 mg, , 1200.0 mg, 800.0 mg, 400.0 mg/mL, 500.0 mg, 1000.0 mg, 375.0 mg, 250.0 mg, 10.0 mg/mL, 40.0 mg/mL, 0.4 mg/mg, 20.0 mg/mL, 200.0 mg/mL, 1000.0 mg/pump actuation, 0.2 mg/mg
, Tablet, delayed release, Oral, Tablet, delayed release - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Enema, Tablet, Capsule - Oral, Tablet - Oral, Capsule, Rectal, Capsule, extended release - Oral, Capsule, extended release, Suppository, Suppository - Rectal, Tablet, extended release, Tablet, extended release - Oral, Enema; Liquid, Suspension, Suspension - Rectal, Enema - Rectal, Tablet, Delayed Release - Oral, Tablet, Delayed Release, Kit - Rectal, Enema; Liquid - Rectal, Kit
Ulcerative Colitis
400.0 mg, , 1200.0 mg, 800.0 mg, 400.0 mg/mL, 500.0 mg, 1000.0 mg, 375.0 mg, 250.0 mg, 10.0 mg/mL, 40.0 mg/mL, 0.4 mg/mg, 20.0 mg/mL, 200.0 mg/mL, 1000.0 mg/pump actuation, 0.2 mg/mg
, Tablet, delayed release, Oral, Tablet, delayed release - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Enema, Tablet, Capsule - Oral, Tablet - Oral, Capsule, Rectal, Capsule, extended release - Oral, Capsule, extended release, Suppository, Suppository - Rectal, Tablet, extended release, Tablet, extended release - Oral, Enema; Liquid, Suspension, Suspension - Rectal, Enema - Rectal, Tablet, Delayed Release - Oral, Tablet, Delayed Release, Kit - Rectal, Enema; Liquid - Rectal, Kit
Proctocolitis
400.0 mg, , 1200.0 mg, 800.0 mg, 400.0 mg/mL, 500.0 mg, 1000.0 mg, 375.0 mg, 250.0 mg, 10.0 mg/mL, 40.0 mg/mL, 0.4 mg/mg, 20.0 mg/mL, 200.0 mg/mL, 1000.0 mg/pump actuation, 0.2 mg/mg
, Tablet, delayed release, Oral, Tablet, delayed release - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Enema, Tablet, Capsule - Oral, Tablet - Oral, Capsule, Rectal, Capsule, extended release - Oral, Capsule, extended release, Suppository, Suppository - Rectal, Tablet, extended release, Tablet, extended release - Oral, Enema; Liquid, Suspension, Suspension - Rectal, Enema - Rectal, Tablet, Delayed Release - Oral, Tablet, Delayed Release, Kit - Rectal, Enema; Liquid - Rectal, Kit
Crohn Disease
400.0 mg, , 1200.0 mg, 800.0 mg, 400.0 mg/mL, 500.0 mg, 1000.0 mg, 375.0 mg, 250.0 mg, 10.0 mg/mL, 40.0 mg/mL, 0.4 mg/mg, 20.0 mg/mL, 200.0 mg/mL, 1000.0 mg/pump actuation, 0.2 mg/mg
, Tablet, delayed release, Oral, Tablet, delayed release - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Enema, Tablet, Capsule - Oral, Tablet - Oral, Capsule, Rectal, Capsule, extended release - Oral, Capsule, extended release, Suppository, Suppository - Rectal, Tablet, extended release, Tablet, extended release - Oral, Enema; Liquid, Suspension, Suspension - Rectal, Enema - Rectal, Tablet, Delayed Release - Oral, Tablet, Delayed Release, Kit - Rectal, Enema; Liquid - Rectal, Kit
Colitis, Ulcerative
400.0 mg, , 1200.0 mg, 800.0 mg, 400.0 mg/mL, 500.0 mg, 1000.0 mg, 375.0 mg, 250.0 mg, 10.0 mg/mL, 40.0 mg/mL, 0.4 mg/mg, 20.0 mg/mL, 200.0 mg/mL, 1000.0 mg/pump actuation, 0.2 mg/mg
, Tablet, delayed release, Oral, Tablet, delayed release - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Enema, Tablet, Capsule - Oral, Tablet - Oral, Capsule, Rectal, Capsule, extended release - Oral, Capsule, extended release, Suppository, Suppository - Rectal, Tablet, extended release, Tablet, extended release - Oral, Enema; Liquid, Suspension, Suspension - Rectal, Enema - Rectal, Tablet, Delayed Release - Oral, Tablet, Delayed Release, Kit - Rectal, Enema; Liquid - Rectal, Kit
Warnings
Sfrowasa Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Mesalazine may interact with Pulse Frequency
There are 20 known major drug interactions with Sfrowasa.
Common Sfrowasa Drug Interactions
Drug Name
Risk Level
Description
Macimorelin
Major
The therapeutic efficacy of Macimorelin can be decreased when used in combination with Mesalazine.
Methotrexate
Major
The serum concentration of Methotrexate can be increased when it is combined with Mesalazine.
Mifamurtide
Major
The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Mesalazine.
Neomycin
Major
The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Neomycin.
Omacetaxine mepesuccinate
Major
The risk or severity of bleeding can be increased when Mesalazine is combined with Omacetaxine mepesuccinate.
Sfrowasa Toxicity & Overdose Risk
In animal studies, mesalazine was found to not increase the risk of cancer in rats, and did not cause any changes in fertility or reproductive health. Symptoms of an overdose on mesalazine can include nausea, vomiting, rapid breathing, ringing in the ears, confusion, and seizures. If an overdose occurs, medical attention should be sought immediately and may include treatments to limit the absorption of the drug, as well as fluids or electrolytes to balance out the body. Patients with impaired kidney function should be monitored carefully for any adverse reactions to mesalazine.
Sfrowasa Novel Uses: Which Conditions Have a Clinical Trial Featuring Sfrowasa?
At present, 96 active studies are investigating the potential of Sfrowasa to mitigate the symptoms of Ulcerative Colitis.
Condition
Clinical Trials
Trial Phases
Proctocolitis
0 Actively Recruiting
Proctitis
0 Actively Recruiting
Crohn Disease
0 Actively Recruiting
Colitis, Ulcerative
0 Actively Recruiting
Ulcerative Colitis
0 Actively Recruiting
Sfrowasa Reviews: What are patients saying about Sfrowasa?
3.3
Patient Review
6/29/2011
Sfrowasa for Ulcerated Colon
Patient Q&A Section about sfrowasa
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.